NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Remix Therapeutics

Remix Therapeutics

Private
Watertown, MassachusettsHealthcare & Life Scienceshttps://www.remixtx.com/

Last Round

Private Placement

Jun 24, 2026

Est. Valuation

$326M

Total Funding Raised

$183M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Remix Therapeutics is a biotechnology company that develops small molecule therapies designed to reprogram RNA processing to treat diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryRNA modulationsmall molecule therapymRNA degraderbiotechclinical-stage biotechoncologyundruggable targetsRNA therapeuticsdrug pipelinecomputational biologybiopharmaadenoid cystic carcinomaACC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Remix Therapeutics Comparables

Compare Remix Therapeutics with similar companies based on industry and business-model similarity.

Remix Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Arrakis Therapeutics
86%
Skyhawk Therapeutics
80%
Accent Therapeutics
80%

Remix Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private PlacementJun 24, 2026
VC RoundJan 3, 2024
Series BMay 17, 2022
Series ADec 8, 2020

Key People

Founding team and executive leadership

Peter Smith

Co-Founder, President And CEO, Co-Founder, President And CSO

Founding Team

Heather Wasserman

COO CBO

Executive Team

Remix Therapeutics Investors

Notable investors and investment history

Remix Therapeutics investors
InvestorRounds
The Column GroupSeries A, Private Placement, Series B, Seed, VC Round
Surveyor CapitalVC Round, Series B
ARCH Venture PartnersSeries A, VC Round, Series B
The Chernin GroupSeries A, Series B, VC Round
ARCH Venture PartnersSeries A, VC Round, Series B
Forge Life Science PartnersPrivate Placement
Foresite CapitalVC Round, Private Placement, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 37% MoM, reaching 4.5K.

  • Apr 21, 2026

    Results from Phase 1/2 ARIA Trial of REM-422 to be presented at 2026 ASCO Annual Meeting.

Remix Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Remix Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Remix Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWatertown, Massachusetts
Employee Range52
Year Founded2019
Last FundingJun 24, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.